NFKB1 and chronic obstructive pulmonary disease: The intranasal administration of LPS accelerated CS-induced bronchial inflammation, similar to that observed in patients with COPD, by promoting neutrophil/macrophage accumulation, ROS/cytokine/chemokine formation, and MAPK/NF-κB activation in experimental COPD mice [18, 22].